**Cosmetic and Biological Benefits of ZenakineTM Revealed**
Croda Beauty team presents ZenakineTM to a full auditorium at the in-cosmetics Global 2025 meeting in Amsterdam, receiving a standing ovation from the audience.
- The presentation showcased the cosmetic benefits of ZenakineTM, including its ability to improve cell longevity and skin regeneration for increased anti-ageing.
- Additional biological mechanisms of ZenakineTM were also revealed, including the reduction of cortisol damage via melatonin production and resynchronisation of the peripheral skin biological clock.
The Croda Beauty team’s technical presentation was a huge success, with the audience being wowed by the cosmetic benefits of ZenakineTM. However, what was also revealed at the launch was the additional biological mechanisms behind the product. These included the improvement of cell longevity and skin regeneration, which can help to increase the effectiveness of anti-ageing treatments.
| Key Benefits of ZenakineTM | Biological Mechanisms |
| Improvement of cell longevity and skin regeneration for increased anti-ageing | Reduction of cortisol damage via melatonin production to promote better sleep |
| Resynchronisation of the peripheral skin biological clock to improve circadian rhythm | Reduction of residual tension improving skin regeneration and avoiding the appearance of expression wrinkles |
The management team of SkinBioTherapeutics sees no reason for the reduction in share price following the global launch of ZenakineTM. The CEO, Stuart Ashman, stated that the positive reception from the audience was “very exciting to see” and that the presentation received a standing ovation from the audience.
“Stuart Ashman, CEO of SkinBioTherapeutics said: ‘The Croda Beauty team held a technical presentation to a completely full auditorium (standing room only) and presented on the cosmetic active ingredient and its benefits – as we had expected and so much more. The positive reception from the audience was very exciting to see.'” – SkinBioTherapeutics plc
The SkinBioTherapeutics team will hold an Investor Meet Company presentation on Wednesday, 16th April 2025, to discuss the additional and significant attributes of ZenakineTM, its applications, and commercialisation. The presentation will be open to all existing and potential shareholders, and questions can be submitted pre-event via the Investor Meet Company dashboard.
Key Highlights of the Investor Meet Company Presentation
- The presentation will update shareholders on the HY results and the launch of ZenakineTM.
- Investors can submit questions pre-event via the Investor Meet Company dashboard up until 15th April 2025.
- The presentation will be open to all existing and potential shareholders.
SkinBioTherapeutics is a life science company focused on skin health, with a proprietary platform technology based on discoveries made by the translational dermatology team at the University of Manchester. The company has five pillars of business, including cosmetic skincare and food supplements to modulate the immune system through the gut-skin axis. The company is also acting as a consolidator and is making acquisitions in complementary areas such as skin care and cosmetic applications.
Overall, the success of Croda Beauty’s technical presentation at In-Cosmetics Global 2025 highlights the potential of ZenakineTM as a cosmetic and biological active ingredient. With its additional benefits and significant attributes, ZenakineTM is poised to make a significant impact in the skin healthcare market. Key Points to Remember
* ZenakineTM has been launched globally by Croda Beauty with a full auditorium of attendees. * The cosmetic benefits of ZenakineTM include the improvement of cell longevity and skin regeneration for increased anti-ageing. * Additional biological mechanisms of ZenakineTM include the reduction of cortisol damage via melatonin production and resynchronisation of the peripheral skin biological clock. * The management team of SkinBioTherapeutics sees no reason for the reduction in share price following the global launch of ZenakineTM. * An Investor Meet Company presentation will be held on Wednesday, 16th April 2025, to discuss the additional and significant attributes of ZenakineTM, its applications, and commercialisation.
